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• The	topic	was	selected	to	educate	health	care	professionals	on	the	complex	pathophysiological	process	of	chronic	inflammatory	demyelinating	polyneuropathy	(CIDP).
• CIDP	is	an	autoimmune	disease	of	the	peripheral	nervous	system	in	which	the	myelin	sheath	surrounding	nerves	is	attacked,	leading	to	improper	conduction	of	nerve	impulses	to	peripheral	nerves	(Greer	&	Wolf,	2015).
• There	are	three	courses	CIDP	can	take;	progressive,	relapsing-remitting,	or	monophasic	(Schaik	et	al.,	2016,	p.2).
• Regardless	of	clinical	course,	initial	presentation	is	nonspecific	and	gradual	(Alabdali	et	al.,	2017,	p.223).
• Progressive	course:	unrelenting	progression	of	symptoms	with	limited	to	no	improvement	or	stabilization.
• Relapsing-remitting	course:	periods	of	exacerbations	with	increased	symptoms	accompanied	by	periods	of	remission.
• Monophasic:	one	occurrence	of	symptoms	that	is	treated	and	resolves	(van	Shaik	et	al.,	2016,	p.	3).
• Multiple	sources	debate	whether	CIDP	is	over	or	under-diagnosed,	but	prevalence	is	currently	estimated	at	1	to	2	per	100,000	adults	(Reynolds,	Sachs	&	Stavros,	2016,	p.32).
• CIDP	is	more	common	in	males	than	females,	and	is	most	commonly	diagnosed	between	ages	40-60	(Reynolds,	Sachs	&	Stavros,	2016,	p.32-33).
• CIDP	has	treatments	available,	but	not	all	courses	of	disease	may	be	corrected	with	available	treatments,	and	progressive	accumulation	of	disability	may	occur	(van	Shaik	et	al.,	2016,	p.	3).
• The	majority	of	patients	with	CIDP	require	long-term	management	and	treatment	(van	Shaik	et	al.,	2016,	p.	3).
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• A	male	between	40	and	60	years	of	age	noticed	gradual	onset	of	bilateral	weakness	of	his	lower	extremities,	then	numbness,	and	lastly	difficulty	walking	over	the	course	of	several	months.
• He	presented	to	his	physician,	who	performed	a	thorough	neurological	assessment	and	nerve	conduction	studies	(NCS).		His	physician	also	completed	an	MRI	and	spinal	tap	to	rule	out	other	potential	diagnoses.	After	obtaining test results, his	physician	confirmed	his	diagnosis	of	CIDP.	(Kang	et	al.,	2013,	p.1-2)
• He	was	initially	treated	with	steroids,	but	did	not	show	improvement,	so	he	was	started	on	a	maintenance	therapy	of	IVIG	every	three	weeks.
• Complete	thorough	neurological	assessments.
• Involve	physical	and	occupational	therapy	in	management	of	weakness	and	sensation	abnormalities	and	the	impact	of	symptoms	on	activities	of	daily	living.
• Educate	patient	and	family	members	on	CIDP.
• Encourage	a	healthy	and	well-balanced	diet
• Monitor	progression	of	disease	process	(GBS/CIDP	Foundation	International,	2018).
• CIDP	creates	neurological	disability	which	sometimes	leads	to	decreased	functional	status	and	decreased	quality	of	life	(Alabdali	et	al.,	2017,	p.223).
• Diagnosis	of	CIDP	is	based	on	thorough	history	and	neurological	assessment,	as	well	as	the	presence	of	demyelination	on	nerve	conduction	studies	(Alabdali	et	al.,	2017,	p.224).
• Cerebral	spinal	fluid	will	show	elevated	protein	levels,	and	MRI	imaging	will	show	enhanced	nerve	roots	(Alabdali	et	al.,	2017,	p.224).
• Symptoms	present	in	three	categories,	sensory,	motor,	and	autonomic	dysfunction	(Alabdali	et	al.,	2017,	p.223).
• Motor	symptoms	typically	present	first	and	include	weakness,	especially	in	lower	limbs,	loss	of	deep	tendon	reflexes,	unsteady	gait,	and	fatigue.
• Sensory	symptoms	include	numbness,	paresthesia	in	a	“stocking-glove”	pattern,	diminished	sensation,	and	burning	sensations	(Reynolds,	Sachs	&	Stavros,	2016,	p.32-34).
• Autonomic	dysfunction	related	to	CIDP	was	previously	thought	to	be	rare,	but	one	study	showed	up	to	86%	of	patients	with	CIDP	experience	autonomic	dysfunction	(Pasangulapati,	2017,	p.	276).
• Autonomic	symptoms	include	orthostatic	hypotension,	exercise	intolerance,	palpitations,	dizziness,	weakness,	and	vision	disturbances	(Adamec	et	al.,	2016,	p.1163).
• Characterized	by	a	slow	progression	of	symptoms	that	reaches	its	peak	greater	than	2	months	after	symptom	onset	(Ripellino,	Fleetwood,	Cantello,	&	Cristoforo,	2014).
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• CIDP	symptoms	are	a	result		of	immune-mediated	destruction	of	peripheral	nerves.
• Acts	on	both	the	cellular	and	the	humoral	pathways	of	the	immune	system.
• “Activated	T	lymphocytes	invade	the	peripheral	nervous	system	through	derangement	of	the	blood	brain	barrier.		Once	within	the	peripheral	nervous	system	these	activated	T	cells	generate	pro-inflammatory	cytokines	and	produce	cytotoxic	activity	against	myelin”	(Reynolds,	Sachs	&	Stavros,	2016,	p.32).
• T	cells	are	the	main	antagonists	of	myelin	sheath	with	“T	cells,	especially	T	helper	1	(Th1)	and	T	helper	17	(Th17)	on	one	side	and	T	regulatory	(T	reg)	on	the	other”	(Ripellino et al.,	2014).
• While	pathogenesis	is	not	fully	understood,	macrophages,	cytokines,	and	complement	are	also	involved	in	degradation	of	myelin	(Ripellino et	al.,	2014).
• Immune	response	potentially	targets	antigens	on	peripheral	nerves,	such	as	myelin	protein	zero,	myelin	basic	protein,	connexin 32,	and	gangliosides	(Reynolds,	Sachs	&	Stavros,	2016,	p.32-33)
• Activated	T	cells	survive	apoptosis	as	a	result	of	an	altered	Faspathway	function	(Ripellino et	al.,	2014).
• “The	myelin	sheath	is	composed	of	various	proteins,	such	as	myelin	protein	zero,	which	account	for	more	than	50	percent	of	the	total	membrane	protein	in	human	peripheral	nervous	system	myelin”	(Köller et	al.,	2003).
• Pharmacological	immunosuppression	with	medications	such	as	azathioprine,	methotrexate,	and	cyclophosphamide	(Ripellino et	al.,	2014).
• Intravenous	or	subcutaneous	immunoglobulin	administered	approximately	every	three	weeks	(van	Shaik	et	al.,	2016,	p.	3).
• Intravenous	or	oral	steroids	(van	Shaik	et	al.,	2016,	p.	3).
• 70%	of	patients	respond	to	immunotherapy	(Ripellino,	Fleetwood,	Cantello,	&	Cristoforo,	2014).
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• It	is	likely	that	many	subtypes	of	CIDP	exist	(Reynolds,	Sachs	&	Stavros,	2016,	p.32).
• More	research	is	needed	to	pinpoint	the	exact	antigens	targeted	in	CIDP,	specifically	for	each	subtype	of	CIDP	(Reynolds,	Sachs	&	Stavros,	2016,	p.32).
• Approximately	70%	of	patients	respond	to	immunomodulation	therapy,	but	as	patients	have	different	subtypes,	some	patients	are	difficult	to	treat	and	research	pinpointing	specific	proteins	linked	to	CIDP	is	necessary	(Ripellino et	al.,	2014).
• In	the	future,	treatments	may	be	specifically	designed	for	patients	on	a	case	by	case	basis	after	identification	of	the	pretense	of	specific	proteins	such	as	CNTN1	and	NF155	(Reynolds,	Sachs	&	Stavros,	2016,	p.34).
Figure	3:	Immunopathogenesis of	CIDPRetrived from:	Köller,	H.,	Kieseier,	B.C.,	Jander,	S.,	&	Hartung,	H.C.	(2003).	Chronic	inflammatory	demyelinating	polyneuropathy. The	New	England	journal	of	medicine,	352	13,	1343-56.
Conclusion
• CIDP	is	a	complex	autoimmune	demyelinating	disorder	that	commonly	impacts	patient’s	quality	of	life	and	activities	of	daily	living		(Alabdali	et	al.,	2017,	p.224).
• More	research	is	needed	to	improve	diagnosis	and	treatments	for	specific	subtypes	of	CIDP,	which	will	improve	patient	outcomes	(Ripellino et	al.,	2014).
